Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue.

Karris MY, Jain S, Bowman VQ, Rieg G, Goicoechea M, Dube MP, Kerkar S, Kemper C, Diamond C, Sun X, Daar ES, Haubrich RH, Morris S; California Collaborative Treatment Group (CCTG) 589 Study Team.

J Acquir Immune Defic Syndr. 2016 Jun 1;72(2):e48-50. doi: 10.1097/QAI.0000000000000990. No abstract available.

2.

Safety of Seasonal Influenza Vaccination in Hospitalized Surgical Patients: A Cohort Study.

Tartof SY, Qian L, Rieg GK, Yu KC, Sy LS, Tseng HF, Hechter RC, Jacobsen SJ.

Ann Intern Med. 2016 May 3;164(9):593-9. doi: 10.7326/M15-1667. Epub 2016 Mar 15.

PMID:
26974053
3.

A Comprehensive Assessment Across the Healthcare Continuum: Risk of Hospital-Associated Clostridium difficile Infection Due to Outpatient and Inpatient Antibiotic Exposure.

Tartof SY, Rieg GK, Wei R, Tseng HF, Jacobsen SJ, Yu KC.

Infect Control Hosp Epidemiol. 2015 Dec;36(12):1409-16. doi: 10.1017/ice.2015.220. Epub 2015 Sep 21.

PMID:
26387888
4.

Incidence of polymerase chain reaction-diagnosed Clostridium difficile in a large high-risk cohort, 2011-2012.

Tartof SY, Yu KC, Wei R, Tseng HF, Jacobsen SJ, Rieg GK.

Mayo Clin Proc. 2014 Sep;89(9):1229-38. doi: 10.1016/j.mayocp.2014.04.027. Epub 2014 Jul 23.

PMID:
25064782
5.

A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy.

Jacobson JM, Wang H, Bordi R, Zheng L, Gross BH, Landay AL, Spritzler J, Routy JP, Benson C, Aberg J, Tebas P, Haas DW, Tiu J, Coughlin K, Purdue L, Sekaly RP; AIDS Clinical Trials Group (ACTG) A5212 Protocol Team.

J Acquir Immune Defic Syndr. 2014 Aug 1;66(4):399-406. doi: 10.1097/QAI.0000000000000195.

6.

Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study.

Squires KE, Bekker LG, Eron JJ, Cheng B, Rockstroh JK, Marquez F, Kumar P, Thompson M, Campo RE, Mounzer K, Strohmaier KM, Lu C, Rodgers A, Jackson BE, Wenning LA, Robertson M, Nguyen BY, Sklar P; REALMRK Investigators.

AIDS Res Hum Retroviruses. 2013 Jun;29(6):859-70. doi: 10.1089/AID.2012.0292. Epub 2013 Feb 26.

7.

Predictors of the isolated hepatitis B core antibody pattern in HIV-infected and -uninfected men in the multicenter AIDS cohort study.

Witt MD, Lewis RJ, Rieg G, Seaberg EC, Rinaldo CR, Thio CL.

Clin Infect Dis. 2013 Feb;56(4):606-12. doi: 10.1093/cid/cis908. Epub 2012 Oct 22.

8.

Herpes simplex virus type 2 seroprevalence and incidence in acute and chronic HIV-1 infection.

Lagnese M, Daar ES, Christenson P, Rieg G.

Int J STD AIDS. 2011 Aug;22(8):463-4. doi: 10.1258/ijsa.2011.010551. Epub 2011 Jul 8.

9.

Seminal plasma HIV levels in men with asymptomatic sexually transmitted infections.

Rieg G, Butler DM, Smith DM, Daar ES.

Int J STD AIDS. 2010 Mar;21(3):207-8. doi: 10.1258/ijsa.2009.009331.

10.

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.

Eron JJ, Young B, Cooper DA, Youle M, Dejesus E, Andrade-Villanueva J, Workman C, Zajdenverg R, Fätkenheuer G, Berger DS, Kumar PN, Rodgers AJ, Shaughnessy MA, Walker ML, Barnard RJ, Miller MD, Dinubile MJ, Nguyen BY, Leavitt R, Xu X, Sklar P; SWITCHMRK 1 and 2 investigators.

Lancet. 2010 Jan 30;375(9712):396-407. doi: 10.1016/S0140-6736(09)62041-9. Epub 2010 Jan 12.

PMID:
20074791
11.

Body site colonization in patients with community-associated methicillin-resistant Staphylococcus aureus and other types of S. aureus skin infections.

Yang ES, Tan J, Eells S, Rieg G, Tagudar G, Miller LG.

Clin Microbiol Infect. 2010 May;16(5):425-31. doi: 10.1111/j.1469-0691.2009.02836.x. Epub 2009 Aug 18.

12.

Asymptomatic sexually transmitted infections in HIV-infected men who have sex with men: prevalence, incidence, predictors, and screening strategies.

Rieg G, Lewis RJ, Miller LG, Witt MD, Guerrero M, Daar ES.

AIDS Patient Care STDS. 2008 Dec;22(12):947-54. doi: 10.1089/apc.2007.0240.

13.

Platelet count is associated with plasma HIV type 1 RNA and disease progression.

Rieg G, Yeaman M, Lail AE, Donfield SM, Gomperts ED, Daar ES; Hemophilia Growth and Development Study (HGDS).

AIDS Res Hum Retroviruses. 2007 Oct;23(10):1257-61.

PMID:
17961113
14.

Antifungal prophylaxis is effective against murine invasive pulmonary aspergillosis.

Rieg G, Spellberg B, Schwartz J, Fu Y, Edwards JE Jr, Sheppard DC, Ibrahim AS.

Antimicrob Agents Chemother. 2006 Aug;50(8):2895-6. No abstract available.

15.

Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles.

Miller LG, Perdreau-Remington F, Rieg G, Mehdi S, Perlroth J, Bayer AS, Tang AW, Phung TO, Spellberg B.

N Engl J Med. 2005 Apr 7;352(14):1445-53.

16.

Novel inhalational murine model of invasive pulmonary aspergillosis.

Sheppard DC, Rieg G, Chiang LY, Filler SG, Edwards JE Jr, Ibrahim AS.

Antimicrob Agents Chemother. 2004 May;48(5):1908-11.

17.

Lack of cross-hepatotoxicity between fluconazole and voriconazole.

Spellberg B, Rieg G, Bayer A, Edwards JE Jr.

Clin Infect Dis. 2003 Apr 15;36(8):1091-3. No abstract available.

PMID:
12684933
18.

Case report. Successful therapy of disseminated histoplasmosis in AIDS with liposomal amphotericin B.

Rieg GK, Shah PM, Helm EB, Just-Nübling G.

Mycoses. 1999 Apr;42(1-2):117-20.

PMID:
10394860
19.

Unanticipated heterogeneity in growth rate and virulence among Candida albicans AAF1 null mutants.

Rieg G, Fu Y, Ibrahim AS, Zhou X, Filler SG, Edwards JE Jr.

Infect Immun. 1999 Jul;67(7):3193-8.

20.

Expression of the Candida albicans gene ALS1 in Saccharomyces cerevisiae induces adherence to endothelial and epithelial cells.

Fu Y, Rieg G, Fonzi WA, Belanger PH, Edwards JE Jr, Filler SG.

Infect Immun. 1998 Apr;66(4):1783-6.

Supplemental Content

Loading ...
Support Center